ALK

ALK · Variant type: fusion · Fusion partner: NPM1

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Brigatinib	100.0%	0.0%	82.96
2	Lorlatinib	100.0%	0.0%	97.24
3	Gilteritinib	99.8%	0.2%	88.97
4	Entrectinib	99.8%	0.2%	93.69
5	Repotrectinib	99.3%	0.7%	84.21
6	Ceritinib	98.8%	1.2%	95.44
7	Crizotinib	98.7%	1.4%	91.39
8	Nintedanib	92.0%	8.0%	90.23
9	Sunitinib	90.1%	9.9%	91.73
10	Bosutinib	86.9%	13.1%	87.22
11	Pralsetinib	86.0%	13.9%	93.43
12	Alpelisib	85.1%	14.9%	97.22
13	Osimertinib	84.2%	15.8%	97.24
14	Alectinib	75.8%	24.2%	95.49
15	Pacritinib	72.2%	27.8%	88.64
16	Lazertinib	63.8%	36.2%	97.47
17	Ruxolitinib	51.5%	48.5%	98.25
18	Defactinib	51.4%	48.6%	92.68
19	Fostamatinib	41.8%	58.2%	96.74
20	Fedratinib	37.9%	62.1%	96.21
21	Baricitinib	35.0%	65.0%	97.99
22	Tepotinib	35.0%	65.0%	99.75
23	Erlotinib	34.5%	65.5%	99.75
24	Axitinib	33.5%	66.5%	93.23
25	Darovasertib	33.0%	67.0%	96.99

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Brigatinib	100.0%	99.2%	+0.8%
Lorlatinib	100.0%	97.2%	+2.8%
Gilteritinib	99.8%	99.5%	+0.3%
Entrectinib	99.8%	98.8%	+0.9%
Repotrectinib	99.3%	99.4%	-0.0%
Ceritinib	98.8%	98.3%	+0.6%
Crizotinib	98.7%	97.7%	+0.9%
Nintedanib	92.0%	84.9%	+7.1%
Sunitinib	90.1%	87.7%	+2.4%
Bosutinib	86.9%	75.1%	+11.8%
Pralsetinib	86.0%	82.6%	+3.5%
Alpelisib	85.1%	80.7%	+4.5%
Osimertinib	84.2%	80.5%	+3.7%
Alectinib	75.8%	98.6%	-22.8%
Pacritinib	72.2%	55.3%	+16.9%
Lazertinib	63.8%	46.3%	+17.6%
Ruxolitinib	51.5%	52.1%	-0.6%
Defactinib	51.4%	—	—
Fostamatinib	41.8%	—	—
Fedratinib	37.9%	—	—
Baricitinib	35.0%	46.4%	-11.3%
Tepotinib	35.0%	—	—
Erlotinib	34.5%	—	—
Axitinib	33.5%	—	—
Darovasertib	33.0%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 52.2ms